111 related articles for article (PubMed ID: 24909921)
1. Central nervous system prophylaxis in patients with diffuse large B cell lymphoma, are we treating ourselves? A response to the recent BCSH Guideline.
Griffin M; Goddard K; Morley N; Went R; Fletcher A; Wright J
Br J Haematol; 2014 Nov; 167(4):577-9. PubMed ID: 24909921
[No Abstract] [Full Text] [Related]
2. Central nervous system prophylaxis in patients with diffuse large B cell lymphoma, are we treating ourselves? A response to the recent BCSH Guideline - response to Griffin et al.
McMillan A; Ardeshna KM; Cwynarski K; Lyttelton M; McKay P; Montoto S
Br J Haematol; 2014 Nov; 167(4):579-80. PubMed ID: 25040195
[No Abstract] [Full Text] [Related]
3. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
O'Rourke K; Morris K; Kennedy GA
Cancer; 2011 Jun; 117(11):2579-80; author reply 2580-1. PubMed ID: 24048807
[No Abstract] [Full Text] [Related]
4. Secondary central nervous system lymphoma: risk factors and prophylaxis.
Montoto S; Lister TA
Hematol Oncol Clin North Am; 2005 Aug; 19(4):751-63, viii. PubMed ID: 16083835
[TBL] [Abstract][Full Text] [Related]
5. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
[TBL] [Abstract][Full Text] [Related]
6. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology.
McMillan A; Ardeshna KM; Cwynarski K; Lyttelton M; McKay P; Montoto S;
Br J Haematol; 2013 Oct; 163(2):168-81. PubMed ID: 24033102
[TBL] [Abstract][Full Text] [Related]
7. Central nervous system prophylaxis in diffuse large B-cell lymphoma.
Zahid MF; Khan N; Hashmi SK; Kizilbash SH; Barta SK
Eur J Haematol; 2016 Aug; 97(2):108-20. PubMed ID: 27096423
[TBL] [Abstract][Full Text] [Related]
8. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.
Lemma SA; Pasanen AK; Haapasaari KM; Sippola A; Sormunen R; Soini Y; Jantunen E; Koivunen P; Salokorpi N; Bloigu R; Turpeenniemi-Hujanen T; Kuittinen O
Eur J Haematol; 2016 May; 96(5):492-501. PubMed ID: 26153511
[TBL] [Abstract][Full Text] [Related]
9. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
10. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).
Peñalver FJ; Sancho JM; de la Fuente A; Olave MT; Martín A; Panizo C; Pérez E; Salar A; Orfao A;
Haematologica; 2017 Feb; 102(2):235-245. PubMed ID: 27846613
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.
Ghose A; Kundu R; Latif T
Crit Rev Oncol Hematol; 2014 Sep; 91(3):292-303. PubMed ID: 24698003
[TBL] [Abstract][Full Text] [Related]
12. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
[TBL] [Abstract][Full Text] [Related]
13. How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis.
Hall KH; Panjic EH; Valla K; Flowers CR; Cohen JB
Oncology (Williston Park); 2018 Jun; 32(6):303-9. PubMed ID: 29940062
[TBL] [Abstract][Full Text] [Related]
14. [Isolated central nervous system relapse of diffuse large B-cell lymphoma in the era of immunochemotherapy].
Krmek DZ; Ljubić N; Vrbanić L
Acta Med Croatica; 2012 Dec; 66(5):403-7. PubMed ID: 23814970
[TBL] [Abstract][Full Text] [Related]
15. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
16. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
Kim SJ; Hong JS; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Kim YS; Yun HJ; Lee SI; Kim MK; Park EK; Kim WS; Suh C
Oncotarget; 2016 Nov; 7(44):72033-72043. PubMed ID: 27713132
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?
Cheah CY; Seymour JF
Curr Oncol Rep; 2015 Jun; 17(6):25. PubMed ID: 25912004
[TBL] [Abstract][Full Text] [Related]
18. Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: a review of the literature.
Colocci N; Glantz M; Recht L
Semin Neurol; 2004 Dec; 24(4):395-404. PubMed ID: 15637651
[TBL] [Abstract][Full Text] [Related]
19. To protect and defend: central nervous system prophylaxis in patients with non-Hodgkin's lymphoma.
Lim HY; Thiel E; Glantz MJ
Curr Opin Oncol; 2008 Sep; 20(5):495-501. PubMed ID: 19106650
[TBL] [Abstract][Full Text] [Related]
20. Prevention of CNS relapse in diffuse large B-cell lymphoma.
Kridel R; Dietrich PY
Lancet Oncol; 2011 Dec; 12(13):1258-66. PubMed ID: 21933751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
